A Phase 1b Study to Assess the Anti-fatigability Effect of CK-2127107 in Elderly Male and Female Subjects With Limitations in Mobility
Phase of Trial: Phase I
Latest Information Update: 30 Nov 2017
At a glance
- Drugs CK 2127107 (Primary)
- Indications Muscular atrophy
- Focus Therapeutic Use
- Sponsors Astellas Pharma
- 30 Nov 2017 According to a Cytokinetics media release, the results from this trial is anticipated in 2018.
- 26 Oct 2017 According to a Cytokinetics media release, the company expects to continue enrollment in the study in 2017.
- 14 Jul 2017 Planned End Date changed from 25 Jun 2018 to 1 Jun 2018.